
Nightly Pill Could Redefine Sleep Apnea Treatment
A six-month phase 3 study of AD109 (an oral combo of aroxybutynin and atomoxetine) in 646 adults with mild–severe obstructive sleep apnea showed a ~44% drop in the apnea-hypopnea index versus an 18% reduction with placebo, with improved oxygen metrics and about 40% moving to a lower OSA severity category and 18% achieving complete control; AD109 targets neuromuscular pathways to keep throat muscles active, offering an alternative for CPAP-intolerant patients. Safety was mostly mild; 21% discontinued due to side effects. The drug has FDA Fast Track status and an NDA is with the FDA, with potential action in early 2027.
